• Princeton Critical Minerals

  Participated · Series A · Aug 2026

  Princeton Critical Minerals develops and commercializes an integrated technology platform for extracting lithium from brine, including products named Lilypad™, SmartPond™, and E-LiTE™. The company is operating field deployments that produce validation data under industrial conditions. With the new financing, PCM plans to scale manufacturing and expand commercial deployments while building U.S.-based production capabilities. The firm aims to continue advancing its core extraction technologies toward full commercial execution. The company also reported growth in its team as it prepares to execute on upcoming milestones.

• PolyGone Systems

  Participated · Seed · Feb 2026

  Founded in 2021 out of Princeton University, PolyGone Systems develops patented filtration systems that remove 98% of toxic microplastics from water at 90% lower cost than existing alternatives. Its flagship PolyPod™ units are engineered to treat up to 10 million gallons of water per day, targeting municipal wastewater facilities. Complementing the hardware, the company has launched a microplastics analysis service that provides affordable testing for public agencies, private companies, and utilities to assess contamination and regulatory compliance. PolyGone is currently running a wastewater pilot with the Atlantic County Utilities Authority and has signed three additional commercial deployments slated for 2026 across municipal, industrial, and food-and-beverage customers. Near-term plans include mass production of the PolyPod™ systems and the release of an inline PolyCartridge™ filter for industrial water streams. Management positions the company as a future proprietary data and intelligence provider on microplastic pollution, aiming to become indispensable to water authorities and industrial operators. No revenue figures were disclosed in the articles.

• Synchrony Medical

  Participated · Equity · Feb 2026

  Synchrony Medical is a respiratory care technology company focused on improving airway clearance therapy for people with chronic lung conditions. Its flagship product, the FDA-cleared LibAirty™ Airway Clearance System, allows patients to perform daily home treatments that have demonstrated the ability to clear twice as much sputum as conventional therapies while increasing comfort and satisfaction. Commercially launched in late 2025, the device has received strong early adoption from both patients and clinicians. The company plans to use new capital to scale U.S. commercial operations, expand its clinical evidence base, and advance product development. Headquartered in Jersey City, New Jersey, with additional operations in Or Yehuda, Israel, Synchrony collaborates with leading pulmonologists from Sheba Medical Center and has been supported by Edge Medical Ventures’ EdgeLabs and the Israel Innovation Authority. Although revenue and user figures were not disclosed, the oversubscribed nature of the recent round underscores market demand and investor confidence in the company’s growth trajectory.

• Nascent Materials

  Participated · Seed · Jun 2025

  Nascent Materials is building a manufacturing-focused process to produce cathode materials (initially LFP and LMFP) with more consistent particle size and shape. The company’s process reportedly uses less energy and can improve cathode energy density by up to 12% while cutting production costs by about 30%. That consistency helps pack material more tightly and can tolerate lower-purity raw inputs, opening up more domestic supply options. Founder Chaitanya Sharma draws on experience at Tesla’s Gigafactory and as head of iM3NY, where inconsistent material quality contributed to iM3NY’s Chapter 11 filing in January. Nascent positions its technology as a supply-chain play to reduce reliance on China for cathode material. The company says it plans to expand beyond LFP and LMFP to other chemistries, including NMC and lithium-manganese-rich (LMR).

• Lactiga

  Participated · Grant · Sep 2022

  Lactiga develops novel mucosal antibodies derived from human breastmilk and specializes in secretory IgA (sIgA)-based therapeutics using proprietary technologies. Its lead asset, LCTG-001, is described as the first-ever sIgA mucosally-targeted replacement therapy for patients with compromised immune function. LCTG-001 targets patients with conditions such as Common Variable Immune Deficiency (CVID) who lack mucosal immune protection. The program has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Lactiga plans to use recent funding to complete key nonclinical studies and prepare for first-in-human trials. The company emphasizes treating rare pediatric diseases and reducing mortality and chronic infections in vulnerable populations. Lactiga Therapeutics develops antibody programs derived from human milk for patients with primary immunodeficiencies and COVID-19, based on patented technologies. The company has reported positive topline nonclinical efficacy results and is advancing two primary preclinical programs, LCTG-001 (Common Variable Immunodeficiency) and LCTG-002 (COVID-19 and its variants). Lactiga is based in New Jersey and Toronto and plans to use its recent financing and grants to complete preclinical studies and strengthen its intellectual property portfolio. The company intends to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and start human clinical trials in 2023. Lactiga is collaborating with McMaster University and has secured nondilutive support from programs including the New Jersey Commission on Science, Innovation and Technology (CSIT) and Innovation Factory’s SOPHIE program. The funding and grants are positioned to advance R&D, commercialization preparation, and follow-on investment potential. Lactiga is a biotherapeutics company developing anti-infective biologics derived from maternal antibodies in discarded breast milk. Its lead candidate, LCTG-001, is designed for patients with Primary Immunodeficiency Diseases, including Selective IgA Deficiency and Common Variable Immunodeficiency. LCTG-001 is in preclinical studies and is also being evaluated as a potential treatment for COVID-19. The company has secured a $2.0 million NIH R01 Emergency Award to advance its COVID-19 therapeutics program in collaboration with the Icahn School of Medicine at Mount Sinai. Lactiga owns its intellectual property, received patent approval in Canada in 2020, and has patents pending in the US, EU, and Japan with planned filings in Asia including China. The company has won multiple awards and competition placements, and is working to expand relationships with breast milk banks across North America and Europe.

No current team members are available.